- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.05. | CAMBIUM BIO LIMITED: Change of Address | - | ASX | ||
| CAMBIUM BIO Aktie jetzt für 0€ handeln | |||||
| 22.05. | CAMBIUM BIO LIMITED: Initial Director's Interest Notice - Denese Marks | - | ASX | ||
| 22.05. | CAMBIUM BIO LIMITED: Final Director's Interest Notice - Barry Sechos | - | ASX | ||
| 21.05. | CAMBIUM BIO LIMITED: Board and Company Secretary Changes | - | ASX | ||
| 28.04. | CAMBIUM BIO LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report | - | ASX | ||
| 14.04. | CAMBIUM BIO LIMITED: Change of registry address | - | ASX | ||
| 11.04. | CAMBIUM BIO LIMITED: Notice of ceasing to be a substantial holder | - | ASX | ||
| 21.03. | CAMBIUM BIO LIMITED: Cambium Bio - Release of Shares from Escrow | 1 | ASX | ||
| 18.03. | CAMBIUM BIO LIMITED: Notice of change of interests of substantial holder-CMB | - | ASX | ||
| 18.03. | CAMBIUM BIO LIMITED: FDA Approves Cambium Bio's Potency Assay Strategy for Elate | - | ASX | ||
| 12.03. | CAMBIUM BIO LIMITED: Change of Directors Interest Notice | 1 | ASX | ||
| 12.03. | CAMBIUM BIO LIMITED: Notification regarding unquoted securities - CMB | 1 | ASX | ||
| 12.03. | CAMBIUM BIO LIMITED: Application for quotation of securities - CMB | 1 | ASX | ||
| 07.03. | CAMBIUM BIO LIMITED: Mr Chiu - Director Appointment and Appedix 3X | 1 | ASX | ||
| 04.03. | CAMBIUM BIO LIMITED: Results of General Meeting | 1 | ASX | ||
| 03.03. | CAMBIUM BIO LIMITED: Response to queries re Appendices 3X and 3Z | 2 | ASX | ||
| 28.02. | CAMBIUM BIO LIMITED: Update - Proposed issue of securities - CMB | - | ASX | ||
| 27.02. | CAMBIUM BIO LIMITED: Half Year Report and Accounts | - | ASX | ||
| 25.02. | Cambium Bio gains US FDA approval for Phase 3 Elate Ocular dry eye disease trial protocol | 3 | smallcaps.com.au | ||
| 25.02. | CAMBIUM BIO LIMITED: FDA Approves Elate Ocular Phase 3 Clinical Trial Protocol | 1 | ASX |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PHATHOM PHARMACEUTICALS | 8,920 | +90,19 % | Phathom Pharmaceuticals, Inc. - 8-K, Current Report | ||
| AVIDITY BIOSCIENCES | 36,240 | +1,83 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, May 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
| QIAGEN | 40,060 | -0,55 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Qiagen von 47 auf 50 US-Dollar angehoben und die Einstufung auf "Buy" belassen. Analyst Jan Koch zog in seinem am Dienstag... ► Artikel lesen | |
| ARCELLX | 68,10 | +2,81 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 14,370 | +6,37 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| RECURSION PHARMACEUTICALS | 5,485 | +20,02 % | Recursion Pharmaceuticals shares surge on AI model release | ||
| TARSUS PHARMACEUTICALS | 43,920 | -0,39 % | Oppenheimer assumes Tarsus stock at outperform on strong sales | ||
| BIONTECH | 95,35 | +0,05 % | Summit Therapeutics crasht - BioNTech in Sippenhaft | Wie gewonnen, so zerronnen: Die Aktie von Summit Therapeutics brach am vergangenen Freitag an der Nasdaq um rund 30 Prozent ein. Weitere Studiendaten zum großen Hoffnungsträger Ivonescimab, den die... ► Artikel lesen | |
| VERA THERAPEUTICS | 22,760 | -25,69 % | Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy | Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 46,880 | -3,99 % | ROUNDUP/Aktien New York: Knappes Plus - Gelassenheit trotz Zoll-Unruhen | NEW YORK (dpa-AFX) - Die US-Börsen haben am Dienstag knappe Kursgewinne erzielt. Die jüngst wieder aufflackernden, internationalen Handelsstreitigkeiten wegen der amerikanischen Zollpolitik scheinen... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 15,240 | +2,83 % | RBC Capital behält Outperform-Rating für Edgewise Therapeutics-Aktie bei | ||
| JANUX THERAPEUTICS | 26,210 | +5,86 % | Leerink cuts Janux Therapeutics price target to $89, keeps Outperform | ||
| EVOTEC | 7,060 | +0,94 % | Evotec Aktie: Ohne Übernahme sieht es schlecht aus! Auf diese Kursmarke kommt es an! | © Foto: Finanznachrichten (Symbolbild)Zwischen Kursrakete mit Übernahmefantasie und Korrekturmodus Richtung Süden. Der Biotech-Titel aus Hamburg liefert seit Wochen ein Wechselbad der Gefühle. Kann... ► Artikel lesen | |
| 89BIO | 10,250 | +3,12 % | 89bio, Inc.: 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| TREVI THERAPEUTICS | 7,060 | +4,75 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough | Haduvio met the primary endpoint with statistically-significant reductions in 24-hour cough frequency across all dose groups (108 and 54 mg BID p
Patients saw a... ► Artikel lesen |
CAMBIUM BIO LIMITED gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CAMBIUM BIO LIMITED finden Sie auf Wallstreet Online.